Invest at the Frontier of Neurotechnology and AI
Kaleida Capital identifies strategically consequential NeuroAI companies ahead of the market
Why NeuroAI Now?
Advances in neuroscience, artificial intelligence, computing, and bioengineering are converging to create a new generation of companies capable of measuring, interpreting, and interacting with the nervous system.
These technologies are opening new markets across healthcare, computing, consumer technology, and national security. Yet the category remains technically complex and difficult to evaluate using conventional venture frameworks.
Kaleida Capital was built specifically for this opportunity.
Our Investment Edge
We evaluate opportunities with competency that can’t be easily replicated:
Category relationships: Kaleida has a track record of industry leadership across the emerging NeuroAI ecosystem, including neural interfaces, neuromodulation, precision neuroscience, foundational AI, and enabling data infrastructure.
Deep technical fluency: Our team brings advanced training and operating experience across neuroengineering, neural interfaces, bioengineering, artificial intelligence, and clinical technology.
Clinical and regulatory awareness: We assess whether a company’s technical roadmap can translate into meaningful clinical, regulatory, reimbursement, or commercial milestones.
Valuation discipline: We seek differentiated companies at stages and valuations that preserve the potential for asymmetric venture returns.
What We Invest In
Our NeuroAI thesis extends beyond any single device category or clinical market. We focus on the technologies required to measure, interpret, model, augment, and interact with complex biological and cognitive systems—and on the companies building the data, computational, hardware, and delivery infrastructure that make those capabilities possible.
Our areas of focus include:
Neural data generation, acquisition, and infrastructure
Brain–computer interfaces and human–machine interaction
Neuromodulation, bioelectronic medicine, and precision therapeutics
Computational neuroscience and AI models informed by biological intelligence
AI-enabled healthcare, biotechnology, and scientific discovery
Edge AI, energy-efficient computing, and brain-inspired architectures
Sensors, semiconductors, robotics, and physical AI systems
Data platforms, software tools, and infrastructure for personalized human data
We look for companies that control a critical layer of the NeuroAI stack: differentiated data, proprietary hardware, foundational models, enabling software, clinical infrastructure, or trusted interfaces between people and intelligent systems.
Ways to Invest with Kaleida
Fund I offers diversified exposure to a portfolio of early-stage NeuroAI and neurotechnology companies selected and managed through Kaleida’s specialized investment process.
The fund is designed for investors seeking long-term participation in the category through a professionally managed venture portfolio. Investors receive specialized access to companies building the next generation of neural interfaces, precision neuroscience, neurotechnology, and AI systems informed by the human brain.
Best suited for: Family offices, fund-of-funds, strategic investors, RIAs, and individual accredited investors seeking diversified exposure to the NeuroAI ecosystem.
Kaleida Capital Fund I
Strategic & Institutional Partnerships
We work with family offices, corporations, foundations, universities, and other institutions interested in building a deeper strategic presence in neuroscience and AI.
Potential partnerships may include thematic investment programs, sponsored research commercialization, venture-philanthropic initiatives, and ecosystem development.
Kaleida Capital Fund I is offered pursuant to Rule 506(c) of Regulation D. Participation is limited to investors whose accredited investor status has been verified in accordance with applicable requirements. Information on this website is provided for informational purposes and does not constitute investment, legal, or tax advice. Any offering is made only through the applicable definitive offering documents, which should be reviewed in their entirety.